JP2008537481A - Ｇタンパク質シグナリングを阻害する組成物及び方法 - Google Patents

Ｇタンパク質シグナリングを阻害する組成物及び方法 Download PDF

Info

Publication number
JP2008537481A
JP2008537481A JP2008500834A JP2008500834A JP2008537481A JP 2008537481 A JP2008537481 A JP 2008537481A JP 2008500834 A JP2008500834 A JP 2008500834A JP 2008500834 A JP2008500834 A JP 2008500834A JP 2008537481 A JP2008537481 A JP 2008537481A
Authority
JP
Japan
Prior art keywords
protein
sigk
binding
subunit
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008500834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537481A5 (enExample
Inventor
アラン ヴィー スムルカ
ホセ フォント
タベサ ボナチ
Original Assignee
ユニヴァーシティー オブ ロチェスター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ ロチェスター filed Critical ユニヴァーシティー オブ ロチェスター
Publication of JP2008537481A publication Critical patent/JP2008537481A/ja
Publication of JP2008537481A5 publication Critical patent/JP2008537481A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
JP2008500834A 2005-03-07 2006-03-07 Ｇタンパク質シグナリングを阻害する組成物及び方法 Pending JP2008537481A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65926705P 2005-03-07 2005-03-07
PCT/US2006/008031 WO2006096690A2 (en) 2005-03-07 2006-03-07 Compositions and methods for inhibiting g protein signaling

Publications (2)

Publication Number Publication Date
JP2008537481A true JP2008537481A (ja) 2008-09-18
JP2008537481A5 JP2008537481A5 (enExample) 2009-04-30

Family

ID=36953955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008500834A Pending JP2008537481A (ja) 2005-03-07 2006-03-07 Ｇタンパク質シグナリングを阻害する組成物及び方法

Country Status (7)

Country Link
US (2) US20090221691A1 (enExample)
EP (1) EP1868634A4 (enExample)
JP (1) JP2008537481A (enExample)
CN (1) CN101171022A (enExample)
AU (1) AU2006220652A1 (enExample)
CA (1) CA2600946A1 (enExample)
WO (1) WO2006096690A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011040564A1 (ja) * 2009-09-30 2011-04-07 千寿製薬株式会社 特定のペプチド化合物を有効成分として含む眼科用剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523092C (zh) * 2005-05-16 2009-08-05 徐州开达精细化工有限公司 蒽醌型还原染料16,17-二溴紫蒽酮和16,17-二(1’-亚胺基蒽醌基)紫蒽酮及其制备方法
EP2147310A4 (en) * 2007-04-27 2010-09-08 Univ Rochester COMPOSITIONS AND METHODS OF INHIBITING G-PROTEIN SIGNALING
CN105802970A (zh) * 2016-05-30 2016-07-27 东北师范大学 靶向沉默Gβ1的shRNA
US10436795B2 (en) * 2016-09-16 2019-10-08 Institute For Cancer Research Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a protein
CN106908610B (zh) * 2017-03-13 2018-11-02 绍兴康知生物科技有限公司 一种基于受体配体结合技术筛查吸食吗啡的试剂、制备方法及应用
CN108802366B (zh) * 2017-05-04 2020-01-21 中国科学院微生物研究所 一种检测待测样本中目标蛋白的含量的方法
CN115368386A (zh) * 2022-08-09 2022-11-22 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种防治骨性关节炎的小分子化合物及其用途
WO2025157155A1 (zh) * 2024-01-23 2025-07-31 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045179A2 (en) * 1999-01-27 2000-08-03 The Regents Of The University Of California Screening for modulators of g-protein subunit beta 3
US20020106690A1 (en) * 1998-01-07 2002-08-08 Ekkehard Leberer The g-protein b subunit interaction domain of ste20p/pak family of protein kinases and uses thereof in bioassays
JP2002533693A (ja) * 1998-12-23 2002-10-08 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 苦味応答のインヒビター
JP2003510048A (ja) * 1999-09-21 2003-03-18 フォーシス デンタル インファーマリー フォー チルドレン 破骨細胞で発現されるｇ−タンパク質レギュレーターであるｒｇｓ１０ｂ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0548165T3 (da) * 1990-09-13 2001-07-16 Univ Duke Ekspression af G-proteinkoblede receptorer i gær
US7189519B2 (en) * 1998-08-10 2007-03-13 Stc.Unm Bead-based detection of ligand-GPCR-G protein complexes
WO2003062393A2 (en) * 2002-01-22 2003-07-31 Bristol-Myers Squibb Company G protein-coupled receptor variants
US20040121330A1 (en) * 2002-12-18 2004-06-24 Feder John N. Novel human G-protein coupled receptor, HGPRBMY4, and methods of use thereof
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106690A1 (en) * 1998-01-07 2002-08-08 Ekkehard Leberer The g-protein b subunit interaction domain of ste20p/pak family of protein kinases and uses thereof in bioassays
JP2002533693A (ja) * 1998-12-23 2002-10-08 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 苦味応答のインヒビター
WO2000045179A2 (en) * 1999-01-27 2000-08-03 The Regents Of The University Of California Screening for modulators of g-protein subunit beta 3
JP2003510048A (ja) * 1999-09-21 2003-03-18 フォーシス デンタル インファーマリー フォー チルドレン 破骨細胞で発現されるｇ−タンパク質レギュレーターであるｒｇｓ１０ｂ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011040564A1 (ja) * 2009-09-30 2011-04-07 千寿製薬株式会社 特定のペプチド化合物を有効成分として含む眼科用剤

Also Published As

Publication number Publication date
US20090221691A1 (en) 2009-09-03
US20130116313A1 (en) 2013-05-09
CN101171022A (zh) 2008-04-30
WO2006096690A3 (en) 2007-11-08
EP1868634A2 (en) 2007-12-26
AU2006220652A1 (en) 2006-09-14
EP1868634A4 (en) 2010-10-20
US8748480B2 (en) 2014-06-10
CA2600946A1 (en) 2006-09-14
WO2006096690A2 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
US8748480B2 (en) Methods for treating opioid tolerance
US11390646B2 (en) Structure-based peptide inhibitors of α-synuclein aggregation
JP5788430B2 (ja) 抗β１アドレナリン受容体抗体を阻害する手段
Sanchez-Collado et al. Cross-talk between the adenylyl cyclase/cAMP pathway and Ca2+ homeostasis
JP2002531384A (ja) ＢクラスｅｐｈｒｉｎとＰＤＺ領域との相互作用を変調するペプチド
KR101804285B1 (ko) TCTP 이량체형 IgE-의존성 히스타민 방출인자와 이의 수용체간의 결합을 억제하는 TCTP 유래 C-말단 도메인 및 이의 용도
Wang et al. A novel peptide exerts potent immunosuppression by blocking the two-site interaction of NFAT with calcineurin
JP2019507590A (ja) Ｇタンパク質
Bhuvaneshwari et al. Structural and mechanistic insights of CRAC channel as a drug target in autoimmune disorder
JP5495249B2 (ja) 新規化合物、リン酸化阻害剤、インスリン抵抗性改善剤、及び糖尿病の予防乃至治療剤、並びに、スクリーニング方法
Sloan et al. CCDC32 collaborates with the membrane to assemble the AP-2 clathrin adaptor complex
US6498139B1 (en) Remedies for diseases caused by insulin resistance
CN102580091B (zh) 增强阿片镇痛剂的镇痛作用的方法及试剂
CA2405311A1 (en) Multiprotein-complexes comprising a nmda receptor and uses thereof
Zurawski et al. G protein βγ subunits bind to and inhibit the function of multiple Qa-and Qb, c-SNARE isoforms
Rodríguez Molecular Dissection of Ligand Mediated C3aR1 Signaling: Functional Significance for Lipolysis and Other Cellular Functions
US6989362B1 (en) Methods of treating dopamine dysregulation using agents that regulate phosphorylation/dephosphorylation in dopamine signaling
Luu Dissecting the Molecular Mechanism of Temperature Sensing and Regulation in TRP Channels
Li et al. Kiss1/Gpr54 Prevents Bone Loss through Src Dephosphorylation by Dusp18 in Osteoclasts
US20140037547A1 (en) NOVEL PEPTIDIC ACTIVATORS OF TYPE I cGMP DEPENDENT PROTEIN KINASES AND USES THEREOF
WO2003044196A1 (fr) Proteines postsynaptiques
WO2005009469A1 (ja) 新規血糖調節薬及びそのスクリーニング方法
EP1884568A1 (en) Method for identification of compound having antidepressant effect
Birnbaumer Signal transduction by G proteins: basic principles, molecular diversity, and structural basis of their actions
Zhong Regulatory effect of human c-reactive protein on human neutrophil activities: chemotaxis, respiratory burst, and their signaling

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120625